Metraipolis › archive › dc_005cfbd9c3f2
An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany — Europe PMC PMID:41477238
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41477238
- DOI
- 10.3389/fpubh.2025.1667315
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T14:55:52.768Z
- SHA-256 of the archived text
a1cb2fa2dffe35c1df7eef40a27f5b473c17bd799dcd14b4cacac536695c298c- Stable URL of this page
https://metraipolis.com/documento/dc_005cfbd9c3f2
How to cite
An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany — Europe PMC PMID:41477238 — Europe PMC (en), https://europepmc.org/article/MED/41477238 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_005cfbd9c3f2 (Metraipolis archive dc_005cfbd9c3f2, sha256 a1cb2fa2dffe35c1df7eef40a27f5b473c17bd799dcd14b4cacac536695c298c)
BibTeX
@misc{dc005cfbd9c3f2,
title = {An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany — Europe PMC PMID:41477238},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41477238},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_005cfbd9c3f2; sha256 a1cb2fa2dffe35c1df7eef40a27f5b473c17bd799dcd14b4cacac536695c298c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41477238. Agents can read the archived copy with the MCP tool read_document.